ADX-102-UV-005: A phase 3 randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in subjects with non-infectious anterior uveitis

HS 2017-3842
Eye
Sanjay Kedhar, MD
This clinical trial uses an investigational anti-inflammatory eye drop, ADX-102, and the purpose is to compare the effects of ADX-102 to placebo in treating the signs and symptoms of anterior uveitis. 

To participate in this trial, you must meet certain eligibility criteria which include:

  • You must be between 18 and 85 years of age.
  • You must have an onset of an episode of non-infectious anterior uveitis in the last 2 weeks.
  • You must agree to attend all the study visits and use the drops as instructed by your doctor.
  • You must meet all other eligibility criteria.
If you choose to take part in this clinical trial and are eligible, your participation will last approximately 5 weeks. You will use the eye drops in your study eye(s) for the first four weeks of the trial.
Participation in this trial may help the development of an alternative treatment to uveitis. Taking part in a clinical trial is entirely voluntary. It is important that you take your time to decide whether you want to participate. If you decide to participate, you can change your mind at any time.
All the trial-related exams and the investigational drug will be provided at no cost to you. You will be compensated for your time and inconvenience and reimbursed for reasonable out-of-pocket travel expenses to attend the clinic visits.
ADX-102
Drug therapy
Rosie Magallon, senior clinical research coordinator, or Rachel R. Lane, assistant clinical research coordinator, Department of Ophthalmology, UC Irvine School of Medicine
949-824-8297
949-824-0429